Bone effects: Aromasin (exemestane) is an aromatase Inhibitor(AI) which when used to treat breast cancer causes effects on the bone density which can lead to osteoporosis in some women. So monitoring of Bone mineral density(BMD) is recommended and appropriate treatment offered if there is a significant bone loss after 1-2 years of use of this drug. Ask your doctor more about this issue.
Answered 10/18/2015
2.1k views
2 doctors weighed in across 2 answers
4 doctors weighed in across 2 answers
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question